Multifaceted Roles of Interleukin-6 in Adipocyte–Breast Cancer Cell Interaction

Breast cancer is the most common malignancy in women worldwide, with a developmental process spanning decades. The malignant cells recruit a variety of cells including fibroblasts, endothelial cells, immune cells, and adipocytes, creating the tumor microenvironment. The tumor microenvironment has emerged as active participants in breast cancer progression and response to treatment through autocrine and paracrine interaction with the malignant cells. Adipose tissue is abundant in the breast cancer microenvironment; interactions with cancer cells create cancer-associated adipocytes which produce a variety of adipokines that influence breast cancer initiation, metastasis, angiogenesis, and cachexia. Interleukin (IL)-6 has emerged as key compound significantly produced by breast cancer cells and adipocytes, with the potential of inducing proliferation, epithelial-mesenchymal phenotype, stem cell phenotype, angiogenesis, cachexia, and therapeutic resistance in breast cancer cells. Our aim is to present a brief knowledge of IL-6’s role in breast cancer. This review summarizes our current understanding of the breast microenvironment, with emphasis on adipocytes as key players in breast cancer tumorigenesis. The effects of key adipocytes such as leptin, adipokines, TGF-b, and IL-6 are discussed. Finally, we discuss the role of IL-6 in various aspects of cancer progression.

[1]  Yitao Wang,et al.  Adiponectin and breast cancer , 2011, Medical oncology.

[2]  S. Ivy,et al.  Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition , 2011, Breast Cancer Research.

[3]  A. Tzankov,et al.  Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.

[4]  S. Kihara,et al.  Association of serum adiponectin levels with breast cancer risk. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  E. Palmer,et al.  Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.

[6]  S. Iwase,et al.  Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. , 2004, European cytokine network.

[7]  B. Mroczko,et al.  [Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease]. , 2007, Polskie Archiwum Medycyny Wewnetrznej.

[8]  C. Giordano,et al.  The Multifaceted Mechanism of Leptin Signaling within Tumor Microenvironment in Driving Breast Cancer Growth and Progression , 2014, Front. Oncol..

[9]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  J. Coward,et al.  Interleukin-6: an angiogenic target in solid tumours. , 2014, Critical reviews in oncology/hematology.

[11]  Mark A. LaBarge On stem cells in the human breast. , 2012, Cold Spring Harbor perspectives in biology.

[12]  D. Weaver,et al.  Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. , 2001, Cancer research.

[13]  W. Jung,et al.  Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells , 2015, Breast Cancer Research and Treatment.

[14]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[15]  Mihail I Mitov,et al.  Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer , 2017, Cell Death & Disease.

[16]  R. DiMarchi,et al.  Leptin: structure, function and biology. , 2005, Vitamins and hormones.

[17]  Xin-hua Liang,et al.  Links between cancer stem cells and epithelial–mesenchymal transition , 2015, OncoTargets and therapy.

[18]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[19]  L. Hebbard,et al.  Role of Adiponectin and Its Receptors in Cancer , 2012, Cancer biology & medicine.

[20]  R. Alten,et al.  Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases , 2013, Annals of medicine.

[21]  J. Rossi,et al.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer , 2010, British Journal of Cancer.

[22]  B. Miroux,et al.  The biology of mitochondrial uncoupling proteins. , 2004, Diabetes.

[23]  J. Li,et al.  CNTO-328 (Centocor). , 2005, Current opinion in investigational drugs.

[24]  Hsin C. Lin,et al.  Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade. , 2016, Cancer research.

[25]  G. Strassmann,et al.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.

[26]  Jinxiang Tan,et al.  Adipocyte is a non-trivial, dynamic partner of breast cancer cells. , 2011, The International journal of developmental biology.

[27]  P. Lewandowski,et al.  Cancer cachexia: impact, mechanisms and emerging treatments , 2012, Journal of cachexia, sarcopenia and muscle.

[28]  J. Morales-Montor,et al.  The role of cytokines in breast cancer development and progression. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  W. Han,et al.  Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism , 2016, bioRxiv.

[30]  J. Kurebayashi Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications , 2000, Breast cancer.

[31]  R. Carón,et al.  Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer , 2017, Journal of Experimental & Clinical Cancer Research.

[32]  F. Church,et al.  Mature breast adipocytes promote breast cancer cell motility. , 2012, Experimental and molecular pathology.

[33]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[34]  M. Trikha,et al.  CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice , 2004, International journal of cancer.

[35]  B. Cannon,et al.  The browning of white adipose tissue: some burning issues. , 2014, Cell metabolism.

[36]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[37]  D. McMillan,et al.  Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer. , 2016, Translational research : the journal of laboratory and clinical medicine.

[38]  M. Dieudonné,et al.  Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. , 2008, Oncology reports.

[39]  A. Krešo,et al.  Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.

[40]  M. Naylor,et al.  Breast cancer stem cells , 2013, Front. Physiol..

[41]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[42]  C. Dray,et al.  Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. , 2013, Cancer research.

[43]  Kunwei Shen,et al.  Stromal cells in tumor microenvironment and breast cancer , 2012, Cancer and Metastasis Reviews.

[44]  C. Buechler,et al.  Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. , 2009, Endocrine-related cancer.

[45]  J. Bono,et al.  Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.

[46]  P. Seale,et al.  Brown and beige fat: development, function and therapeutic potential , 2013, Nature Medicine.

[47]  Haishi Qiao,et al.  Human Adipocytes Stimulate Invasion of Breast Cancer MCF-7 Cells by Secreting IGFBP-2 , 2015, PloS one.

[48]  C. Ghigna,et al.  EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression , 2017, Molecular Cancer.

[49]  Genevieve Housman,et al.  EMT and tumor metastasis , 2015, Clinical and Translational Medicine.

[50]  E. Matera,et al.  Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity , 2015, Breast Cancer Research.

[51]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[52]  P. Hojman,et al.  The role of intratumoral and systemic IL-6 in breast cancer , 2013, Breast Cancer Research and Treatment.

[53]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[54]  A. Bhatt,et al.  Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.

[55]  Shuwei Wang,et al.  The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). , 2014, International journal of oncology.

[56]  M. D. De Latour,et al.  Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. , 2005, Biochemical and biophysical research communications.

[57]  W. Scherbaum,et al.  Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. , 2001, The Journal of clinical endocrinology and metabolism.

[58]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[59]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[60]  F. Caldefie‐Chézet,et al.  Molecular mechanisms of leptin and adiponectin in breast cancer. , 2011, European journal of cancer.

[61]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[62]  Chia-Hung Chou,et al.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.

[63]  M. Jeschke,et al.  White Adipose Tissue Browning: A Double-edged Sword , 2016, Trends in Endocrinology & Metabolism.

[64]  B. Yu,et al.  Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell , 2005, Archives of pharmacal research.

[65]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[66]  C. Muller Tumour-surrounding adipocytes are active players in breast cancer progression. , 2013, Annales d'endocrinologie.

[67]  M. Prentki,et al.  Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. , 2017, JCI insight.

[68]  K. Baltgalvis,et al.  Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia , 2010, Exercise and sport sciences reviews.

[69]  G. Steinberg,et al.  Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.

[70]  A. Gansmuller,et al.  Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. , 2005, Cancer research.

[71]  L. Coussens,et al.  The tumor microenvironment: a critical determinant of neoplastic evolution. , 2003, European journal of cell biology.

[72]  R. Hovey,et al.  Diverse and Active Roles for Adipocytes During Mammary Gland Growth and Function , 2010, Journal of Mammary Gland Biology and Neoplasia.

[73]  T. Price,et al.  Presence of leptin in breast cell lines and breast tumors. , 1999, Biochemical and biophysical research communications.

[74]  D. Heber,et al.  Preadipocytes stimulate breast cancer cell growth. , 1998, Nutrition and cancer.

[75]  Miao-Fen Chen,et al.  The role of IL-6 in the radiation response of prostate cancer , 2013, Radiation oncology.

[76]  S. Ambs,et al.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.

[77]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[78]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[79]  J. Bromberg,et al.  The IL-6 feed-forward loop: a driver of tumorigenesis. , 2014, Seminars in immunology.

[80]  R. Hollingsworth,et al.  Interleukin-6 Stimulates Defective Angiogenesis. , 2015, Cancer research.

[81]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[82]  R. Datar,et al.  Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. , 2016, Cancer research.

[83]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  D. Saunders,et al.  Adipocyte-Tumor Cell Metabolic Crosstalk in Breast Cancer. , 2017, Trends in molecular medicine.

[85]  Y. Kwon,et al.  Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. , 2013, Cellular signalling.

[86]  D. Rose,et al.  Angiogenesis, adipokines and breast cancer. , 2009, Cytokine & growth factor reviews.

[87]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[88]  Y. DeClerck,et al.  Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.

[89]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[90]  T. Kishimoto,et al.  Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .

[91]  M. Vasson,et al.  Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. , 2008, Oncology reports.

[92]  Qun Zhou,et al.  Adipocyte activation of cancer stem cell signaling in breast cancer. , 2015, World journal of biological chemistry.

[93]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[94]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[95]  A. Xu,et al.  Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner* , 2005, Journal of Biological Chemistry.

[96]  A. Axel,et al.  Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer , 2007 .

[97]  S. Kajimura,et al.  A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. , 2014, Annual review of physiology.

[98]  Toshio Tanaka,et al.  Therapeutic uses of anti-interleukin-6 receptor antibody. , 2015, International immunology.

[99]  Sendurai A Mani,et al.  Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression , 2011, Breast Cancer Research.

[100]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[101]  Bernard Klein,et al.  Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.

[102]  Hugh M. Davis,et al.  Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[103]  Ding Cheng Yang,et al.  Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. , 2011, Anticancer research.

[104]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[105]  F. Sotgia,et al.  Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. , 2014, Seminars in oncology.

[106]  M. Núñez,et al.  Tumor microenvironment and breast cancer progression , 2012, Cancer biology & therapy.

[107]  P. Valet,et al.  Cancer-associated adipocytes promotes breast tumor radioresistance. , 2011, Biochemical and biophysical research communications.

[108]  P. Porporato Understanding cachexia as a cancer metabolism syndrome , 2016, Oncogenesis.

[109]  K. Polyak,et al.  The microenvironment in breast cancer progression: biology and implications for treatment , 2011, Breast Cancer Research.

[110]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[111]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[112]  Y. Liu,et al.  IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures , 2011, International journal of oncology.

[113]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[114]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[115]  Ruo-Pan Huang,et al.  Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.

[116]  Debra L. Fulton,et al.  Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers , 2015, Breast Cancer Research.

[117]  Rong Li,et al.  Interleukin 6 Secreted from Adipose Stromal Cells Promotes Migration and Invasion of Breast Cancer Cells , 2009, Oncogene.

[118]  A. Aboussekhra Role of cancer-associated fibroblasts in breast cancer development and prognosis. , 2011, The International journal of developmental biology.

[119]  E. Lengyel,et al.  Adipose tissue and adipocytes support tumorigenesis and metastasis. , 2013, Biochimica et biophysica acta.

[120]  M. Tisdale Biology of cachexia. , 1997, Journal of the National Cancer Institute.

[121]  N. Yanaihara,et al.  Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary , 2016, Molecular carcinogenesis.

[122]  Yuan Yuan Wang,et al.  Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. , 2011, Cancer research.

[123]  A. Axel,et al.  Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[125]  E. Wagner,et al.  A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. , 2014, Cell metabolism.

[126]  K. Pantel,et al.  The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study , 2011, The Prostate.

[127]  J. Blay,et al.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients , 2003, British Journal of Cancer.

[128]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[129]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[130]  Z. Duan,et al.  Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.

[131]  Yang Yao,et al.  Interleukin-6 as a Prognostic Marker for Breast Cancer: A Meta-analysis , 2015, Tumori.

[132]  K. Jamil,et al.  Adiponectin and Leptin Molecular Actions and Clinical Significance in Breast Cancer , 2014, International journal of hematology-oncology and stem cell research.

[133]  Kinyui A. Lo,et al.  Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes , 2013, Bioscience reports.

[134]  D. Santini,et al.  Interleukin-6 and pro inflammatory status in the breast tumor microenvironment , 2015, World Journal of Surgical Oncology.

[135]  J. Rich,et al.  Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. , 2013, Endocrine-related cancer.

[136]  M. Mandal,et al.  Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. , 2016, Cancer letters.

[137]  Philippe Valet,et al.  Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. , 2012, Cancer letters.

[138]  A. van Oudenaarden,et al.  Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity , 2016, Cell reports.